CTI BioPharma (CTIC) Rating Lowered to Hold at Zacks Investment Research

Zacks Investment Research lowered shares of CTI BioPharma (NASDAQ:CTIC) from a buy rating to a hold rating in a report published on Tuesday morning.

According to Zacks, “CTI BioPharma Corp. is a biopharmaceutical company. It is focused on the acquisition, development and commercialization of therapies covering a spectrum of blood-related cancers. The company is heavily focused on marketing its approved therapy Pixuvri in Europe, and on continuing the development of its late-stage development pipeline, including pacritinib. CTI BioPharma Corp., formerly known as Cell Therapeutics, Inc., is headquartered in Seattle, Washington. “

Other analysts also recently issued reports about the company. Jefferies Group started coverage on CTI BioPharma in a report on Tuesday, September 12th. They set a buy rating and a $7.50 price objective for the company. ValuEngine downgraded CTI BioPharma from a sell rating to a strong sell rating in a report on Wednesday, October 11th.

CTI BioPharma (NASDAQ CTIC) opened at $2.76 on Tuesday. CTI BioPharma has a 52 week low of $2.45 and a 52 week high of $6.48. The company has a current ratio of 2.19, a quick ratio of 2.17 and a debt-to-equity ratio of 0.26.

CTI BioPharma (NASDAQ:CTIC) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.28) EPS for the quarter, topping analysts’ consensus estimates of ($0.32) by $0.04. The business had revenue of $1.71 million during the quarter, compared to the consensus estimate of $0.30 million. CTI BioPharma had a negative return on equity of 209.67% and a negative net margin of 96.91%. analysts anticipate that CTI BioPharma will post -1.2 earnings per share for the current year.

Several hedge funds have recently added to or reduced their stakes in CTIC. OxFORD Asset Management LLP acquired a new stake in shares of CTI BioPharma during the 3rd quarter worth $164,000. JPMorgan Chase & Co. acquired a new stake in shares of CTI BioPharma during the 3rd quarter worth $272,000. Finally, Stonepine Capital Management LLC acquired a new stake in shares of CTI BioPharma during the 2nd quarter worth $7,561,000. Institutional investors and hedge funds own 42.81% of the company’s stock.

TRADEMARK VIOLATION WARNING: “CTI BioPharma (CTIC) Rating Lowered to Hold at Zacks Investment Research” was originally posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece on another domain, it was stolen and republished in violation of United States and international copyright laws. The correct version of this piece can be viewed at https://www.com-unik.info/2018/01/06/cti-biopharma-ctic-rating-lowered-to-hold-at-zacks-investment-research.html.

About CTI BioPharma

CTI BioPharma Corp. (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma (NHL).

Get a free copy of the Zacks research report on CTI BioPharma (CTIC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

What are top analysts saying about CTI BioPharma? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CTI BioPharma and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit